Certain adults with non-Hodgkin's lymphoma may be able to slow down the progression of their cancer by receiving Bexxar® (tositumomab). This product is approved for use in people whose cancer has returned, or who have not adequately responded to other treatments.
As a type of radioimmunotherapy, Bexxar is linked to a radioactive element (Iodine I-131). The Bexxar-Iodine I-131 compound attaches to healthy cells and certain cancer cells, marking the cells to be destroyed by the immune system. Also, because Bexxar contain a radioactive element, it emits radiation that helps destroy both the cell the medicine is attached to and surrounding cancer cells.
(Click Bexxar for more details on this topic. This full-length article explains how the drug works, potential side effects, and why Bexxar is not suitable for some people.)